BMC pulmonary medicine · 2024
Predicting solitary pulmonary lesions in breast cancer patients using 18fluorodeoxyglucose-positron emission tomography/computed tomography combined with clinicopathological characteristics.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Xue Yangyang, Hou Weishu, He Yanhui, Xu Alei, Li Xiaohu
Аннотация
BACKGROUND: Solitary pulmonary nodules (SPNs) remain difficult to diagnose for clinical therapeutic purposes in patients with a history of breast cancer. This study try to investigate the value of 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography/computed tomography (PET/CT) combined with clinicopathological predictors for the differential diagnosis of SPNs in breast cancer patients.
METHODS: One hundred and twenty breast cancer patients with newly detected SPNs were enrolled in the study and divided into a primary lung cancer (PLC) group and a breast cancer metastasis (BCM) group. The clinicopathological characteristics as well as metabolic and morphological characteristics on 18F-FDG-PET/CT images of 120 patients were retrospectively reviewed. The differences of clinicopathological and 18F-FDG-PET/CT characteristics between the two groups were analyzed, and multivariate analyses for the diagnosis of SPNs were performed.
RESULTS: Clinicopathological terms of carcinoembryonic antigen (CEA) and CA15-3 levels exhibited significant differences between PLC and BCM groups (P = 0.005 and P = 0.001, respectively). Metabolic characteristics of 18F-FDG-PET/CT images included FDG uptake, SUVmax of SPNs, hilar and/or mediastinal lymph node metastasis, SUVmax of hilar and/or mediastinal lymph node, and extrapulmonary metastasis showed significant differences between PLC and BCM groups (P = 0.004, P < 0.001, P = 0.01, P = 0.032 and P = 0.023, respectively). The lobulation sign, spicule sign, and pleural indentation sign were identified as statistically different morphological features of PLC in CT images (all P < 0.001). Among these, the SUVmax of SPNs, lobulation sign, and pleural indentation sign were valuable predictive factors for accurate diagnosis of SPNs in breast cancer patients.
CONCLUSIONS: 18F-FDG-PET/CT combined with serum tumor markers are valuable for the diagnosis of SPNs in breast cancer patients.
METHODS: One hundred and twenty breast cancer patients with newly detected SPNs were enrolled in the study and divided into a primary lung cancer (PLC) group and a breast cancer metastasis (BCM) group. The clinicopathological characteristics as well as metabolic and morphological characteristics on 18F-FDG-PET/CT images of 120 patients were retrospectively reviewed. The differences of clinicopathological and 18F-FDG-PET/CT characteristics between the two groups were analyzed, and multivariate analyses for the diagnosis of SPNs were performed.
RESULTS: Clinicopathological terms of carcinoembryonic antigen (CEA) and CA15-3 levels exhibited significant differences between PLC and BCM groups (P = 0.005 and P = 0.001, respectively). Metabolic characteristics of 18F-FDG-PET/CT images included FDG uptake, SUVmax of SPNs, hilar and/or mediastinal lymph node metastasis, SUVmax of hilar and/or mediastinal lymph node, and extrapulmonary metastasis showed significant differences between PLC and BCM groups (P = 0.004, P < 0.001, P = 0.01, P = 0.032 and P = 0.023, respectively). The lobulation sign, spicule sign, and pleural indentation sign were identified as statistically different morphological features of PLC in CT images (all P < 0.001). Among these, the SUVmax of SPNs, lobulation sign, and pleural indentation sign were valuable predictive factors for accurate diagnosis of SPNs in breast cancer patients.
CONCLUSIONS: 18F-FDG-PET/CT combined with serum tumor markers are valuable for the diagnosis of SPNs in breast cancer patients.